These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 35707460)

  • 21. Healthcare resource utilization after initiation of sodium-glucose co-transporter-2 inhibitors versus dipeptidyl peptidase-4 inhibitors or other glucose-lowering drugs in Japanese patients with type 2 diabetes.
    Kohsaka S; Takeda M; Kidani Y; Yajima T
    Diabetes Obes Metab; 2021 Apr; 23 Suppl 2():28-39. PubMed ID: 33835640
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical inertia among patients with type 2 diabetes mellitus treated with DPP-4i and/or SGLT-2i.
    Lanzinger S; Schmid SM; Welp R; Zimmermann A; Fasching P; Wagner S; Holl RW
    Diabetes Res Clin Pract; 2018 Dec; 146():162-171. PubMed ID: 30367902
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Novel glucose lowering agents are associated with a lower risk of cardiovascular and adverse events in type 2 diabetes: A population based analysis.
    Elharram M; Moura CS; Abrahamowicz M; Bernatsky S; Behlouli H; Raparelli V; Pilote L
    Int J Cardiol; 2020 Jul; 310():147-154. PubMed ID: 32303419
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Dementia Diagnosis Is Associated with Changes in Antidiabetic Drug Prescription: An Open-Cohort Study of ∼130,000 Swedish Subjects over 14 Years.
    Secnik J; Xu H; Schwertner E; Hammar N; Alvarsson M; Winblad B; Eriksdotter M; Garcia-Ptacek S; Religa D
    J Alzheimers Dis; 2020; 76(4):1581-1594. PubMed ID: 32741836
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The Effects of DPP-4 Inhibitors, GLP-1RAs, and SGLT-2/1 Inhibitors on Heart Failure Outcomes in Diabetic Patients With and Without Heart Failure History: Insights From CVOTs and Drug Mechanism.
    Pan X; Xu S; Li J; Tong N
    Front Endocrinol (Lausanne); 2020; 11():599355. PubMed ID: 33335511
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Blood Pressure-Lowering Effect of Newer Antihyperglycemic Agents (SGLT-2 Inhibitors, GLP-1 Receptor Agonists, and DPP-4 Inhibitors).
    Liakos CI; Papadopoulos DP; Sanidas EA; Markou MI; Hatziagelaki EE; Grassos CA; Velliou ML; Barbetseas JD
    Am J Cardiovasc Drugs; 2021 Mar; 21(2):123-137. PubMed ID: 32780214
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Does background metformin therapy influence the cardiovascular outcomes with SGLT-2 inhibitors in type 2 diabetes?
    Singh AK; Singh R
    Diabetes Res Clin Pract; 2021 Feb; 172():108536. PubMed ID: 33181201
    [TBL] [Abstract][Full Text] [Related]  

  • 28. SGLT-2 inhibitors and the risk of hospitalization for community-acquired pneumonia: A population-based cohort study.
    Brunetti VC; Reynier P; Azoulay L; Yu OHY; Ernst P; Platt RW; Filion KB
    Pharmacoepidemiol Drug Saf; 2021 Jun; 30(6):740-748. PubMed ID: 33428309
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Renal Benefits of SGLT 2 Inhibitors and GLP-1 Receptor Agonists: Evidence Supporting a Paradigm Shift in the Medical Management of Type 2 Diabetes.
    Ninčević V; Omanović Kolarić T; Roguljić H; Kizivat T; Smolić M; Bilić Ćurčić I
    Int J Mol Sci; 2019 Nov; 20(23):. PubMed ID: 31757028
    [TBL] [Abstract][Full Text] [Related]  

  • 30. EMPA-REG and Other Cardiovascular Outcome Trials of Glucose-lowering Agents: Implications for Future Treatment Strategies in Type 2 Diabetes Mellitus.
    Schernthaner G; Schernthaner-Reiter MH; Schernthaner GH
    Clin Ther; 2016 Jun; 38(6):1288-1298. PubMed ID: 27210264
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparing SGLT-2 inhibitors to DPP-4 inhibitors as an add-on therapy to metformin in patients with type 2 diabetes: A systematic review and meta-analysis.
    Mishriky BM; Tanenberg RJ; Sewell KA; Cummings DM
    Diabetes Metab; 2018 Mar; 44(2):112-120. PubMed ID: 29477373
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [New and old glucose lowering drugs; a state-of-the-art review].
    IJzerman RG; Vrijlandt PJWS
    Ned Tijdschr Geneeskd; 2020 Oct; 164():. PubMed ID: 33201636
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Treatment choices for the glycaemic management of patients with type 2 diabetes and chronic kidney disease: Analysis of the SAIL patient linked dataset.
    Min T; Davies GI; Rice S; Chess J; Stephens JW
    Diabetes Metab Syndr; 2018; 12(2):123-127. PubMed ID: 29239764
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Combination therapy with SGLT2 inhibitors for diabetic kidney disease.
    Cai Y; Liu X; Xu G
    Biomed Pharmacother; 2020 Jul; 127():110192. PubMed ID: 32559844
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparison of New Glucose-Lowering Drugs on Risk of Heart Failure in Type 2 Diabetes: A Network Meta-Analysis.
    Kramer CK; Ye C; Campbell S; Retnakaran R
    JACC Heart Fail; 2018 Oct; 6(10):823-830. PubMed ID: 30196071
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cardiovascular Events Associated With SGLT-2 Inhibitors Versus Other Glucose-Lowering Drugs: The CVD-REAL 2 Study.
    Kosiborod M; Lam CSP; Kohsaka S; Kim DJ; Karasik A; Shaw J; Tangri N; Goh SY; Thuresson M; Chen H; Surmont F; Hammar N; Fenici P;
    J Am Coll Cardiol; 2018 Jun; 71(23):2628-2639. PubMed ID: 29540325
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Use of optimal medical therapy in patients with diabetes and atherosclerotic cardiovascular disease: Insights from a prospective longitudinal cohort study.
    Arnold SV; de Lemos JA; Zheng L; Rosenson RS; Ballantyne CM; Alam S; Bhatt DL; Cannon CP; Kosiborod M;
    Diabetes Obes Metab; 2023 Jun; 25(6):1750-1757. PubMed ID: 36843558
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Novel antidiabetic drugs in diabetic kidney disease accompanying type 2 diabetes - a minireview.
    Wieczorek-Surdacka E; Surdacki A; Świerszcz J; Chyrchel B
    Folia Med Cracov; 2020; 60(4):97-101. PubMed ID: 33821854
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Do GLP-1RAs and SGLT-2is reduce cardiovascular events in women with type 2 diabetes? A systematic review and meta-analysis.
    Mishriky BM; Okunrintemi V; Jain S; Sewell KA; Powell JR; Cummings DM
    Diabetes Metab; 2021 Feb; 47(1):101160. PubMed ID: 32439471
    [TBL] [Abstract][Full Text] [Related]  

  • 40. National trends in the treatment of diabetic nephropathy in the United States.
    Ajiboye O; Segal JB
    J Clin Pharm Ther; 2017 Jun; 42(3):311-317. PubMed ID: 28295491
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.